<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524585</url>
  </required_header>
  <id_info>
    <org_study_id>19-5975</org_study_id>
    <nct_id>NCT04524585</nct_id>
  </id_info>
  <brief_title>Partial Neuromuscular Blockade in Acute Respiratory Distress Syndrome</brief_title>
  <acronym>PNEUMA</acronym>
  <official_title>Partial Neuromuscular Blockade in Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PNEUMA is a preliminary safety and feasibility trial of a novel approach to the titration of&#xD;
      neuromuscular blockade (NMB) to safe spontaneous breathing in patients with severe acute&#xD;
      respiratory distress syndrome (ARDS) supported with veno-venous extracorporeal membrane&#xD;
      oxygenation (VV-ECMO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlling respiratory effort in patients with ARDS can be challenging, as they often&#xD;
      exhibit a very high respiratory drive despite receiving high doses of sedatives.&#xD;
      Consequently, these patients usually receive full neuromuscular blockade, with the goal to&#xD;
      avoid such injurious respiratory efforts. Unfortunately, full neuromuscular blockade is not&#xD;
      without complications. To address this issue, the use of partial neuromuscular blockade has&#xD;
      been proposed as a strategy to maintain respiratory muscle activity while providing lung&#xD;
      protective ventilation.&#xD;
&#xD;
      The objective of this study is to demonstrate the safety and feasibility of safe spontaneous&#xD;
      breathing using partial NMB in severe ARDS patients supported on VV-ECMO.&#xD;
&#xD;
      An esophageal balloon and a catheter will be placed. Once adequate sedation has been ensured,&#xD;
      small boluses of cisatracurium will be administered. Then, an infusion of cisatracurium will&#xD;
      be started to maintain spontaneous breathing at esophageal pressure swings (Pes) of 3-10 cm&#xD;
      H2O or selected diaphragm electrical activity (Edi) targets. After establishing a sedation&#xD;
      and NMB dosing regimen at which safe spontaneous breathing is achieved, we will document&#xD;
      whether these targets can be maintained over a 24-hour period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients achieving and maintaining targeted esophageal pressure swings</measure>
    <time_frame>Assessed after achievement of Pes targets for 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of serious adverse events</measure>
    <time_frame>Assessed maintenance 24 hours phase</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Partial NMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuromuscular blockade</intervention_name>
    <description>Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.</description>
    <arm_group_label>Partial NMB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Potentially injurious respiratory efforts as defined by esophageal pressure swings or&#xD;
             occlusion pressure swing AND Riker Sedation-Agitation Scale (SAS) â‰¤2 (if the clinical&#xD;
             team has elected to sedate to that depth).&#xD;
&#xD;
          2. The medical team has undertaken a trial of discontinuing neuromuscular blockade and&#xD;
             determined that the patient requires reinstitution of neuromuscular blockade to ensure&#xD;
             toleration of ECMO and they are willing for the patient undergo a trial of partial&#xD;
             neuromuscular blockade&#xD;
&#xD;
          3. The patient is receiving neuromuscular blockade with no plan to discontinue&#xD;
             neuromuscular blockade until the next day and the medical team is willing for the&#xD;
             patient to undergo a trial of partial neuromuscular blockade&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decannulation from VV-ECMO is anticipated within 24 hours&#xD;
&#xD;
          2. Contraindication to esophageal catheterization&#xD;
&#xD;
          3. Contraindication to neuromuscular blockade (allergy, history of malignant&#xD;
             hyperthermia)&#xD;
&#xD;
          4. Patient has a condition deemed by the medical team to require complete NMB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewan Goligher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenna Wong, MSc</last_name>
    <phone>4163404800</phone>
    <phone_ext>7613</phone_ext>
    <email>jenna.wong@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Wong, MsC</last_name>
      <email>jenna.wong@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Ewan Goligher</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

